Different standards for name-brand, generic drugs

WASHINGTON — The Supreme Court decision late last month that state-law failure-to-warn claims against generic drug makers are preempted by federal law — handed down just two years after the Court held that brand-name drug makers could face such suits — creates a legal discrepancy that leaves the majority of patients without recourse, some advocates ...

Leave a Reply

Your email address will not be published. Required fields are marked *